Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.

Interestingly, the combined treatment decreased the extent of Akt and ERK1/2 phosphorylation more efficiently than the treatment with aptamer or anti-PD-L1 mAb alone, showing a significant or a decreasing trend, respectively (Fig. 4 d).

also in 47,180 other papers